The Lancet Respiratory Medicine Пульмонология и респираторная медицина
Long-term safety and efficacy of twice-yearly depemokimab in type 2 asthma with an eosinophilic phenotype: 2-year integrated analysis of the phase 3a SWIFT-1 and SWIFT-2 studies and AGILE open-label extension
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.